| Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
| I. MODIFIED AGREEMENTS | |||
| JUNE | |||
| Alder Bio-pharmaceuticals Inc.* | Schering-Plough Corp. | Expanded its collaboration to include potential applications to central nervous system disorders | Alder will receive an up-front payment, committed funding for work on the project and milestone payments tied to the advancement of a therapeutic candidate, as well as future product royalties (6/8) |
| BioSeek Inc.* | Merck KGaA | Three-year collaboration extending and expanding the 2008 compound profiling agreement | BioSeek will continue to use its BioMAP platform to evaluate Merck Serono small-molecule compounds and proteins across multiple therapeutic areas for preclinical development (6/10) |
| Halozyme Therapeutics Inc. (HALO) | F. Hoffmann-La Roche Ltd. (Switzerland) | Partnership under which Roche selected a fifth target to be used with Halozyme's Enhanze biologics drug delivery platform | Roche will pay $4.25M for exclusive global rights to apply its hyaluronidase enzyme, rHuPH20, to the target (6/9) |
| MorphoSys AG (Germany; BE:MOR) | Schering-Plough Corp. | Schering-Plough triggered its option to extend the current antibody collaboration for another year | The deal grants Schering-Plough continued access to MorphoSys's antibody library HuCAL GOLD at its research site in Palo Alto, Calif. (6/16) |
| Trubion Pharmaceuticals Inc. (TRBN) | Wyeth | Agreement under which Wyeth exercised an option to extend research for one year, through Dec. 22, 2010 | Wyeth's obligations include research funding of about $3.3M in exchange for committed research services; the deal involves Trubion's TRU-015 and other therapeutics (6/23) |
| JULY | |||
| Alnylam Pharmaceuticals Inc. (ALNY) | Novartis AG (Switzerland) | Agreement to extend the RNAi therapeutics collaboration for a fifth and final planned year, through October 2010 | The deal was started in October 2005 and is focused on the discovery, development and commercialization of RNAi therapeutics toward a defined number of Novartis-selected disease gene targets (7/17) |
| Cellular Dynamics International* | Roche AG (Switzerland) | Agreement to expand their existing agreement to test drug development candidates for their potential to cause cardiotoxicity | CDI will supply purified cardiomyocytes created from induced pluripotent stem cells to Roche, and the two companies will collaborate to perform various cell characterization, toxicological and electro-physiological response experiments (7/1) |
| MicroDose Therapeutx Inc.* | Merck & Co. Inc. | Exercised option to extend Merck's license to the MicroDose Dry Powder Inhaler technology to an additional investigational compound | The exercise triggers the payment of an undisclosed fee to MicroDose (7/22) |
| MorphoSys AG (Germany; FSE:MOR) | Novartis AG (Switzerland) | Agreement under which Novartis committed to the 10-year term of its 2007 alliance following achievement by MorphoSys of certain predefined improvements in its technologies | The collaboration will run until 2017 and can be extended by Novartis for an additional two years (7/6) |
| II. TERMINATED AGREEMENTS | |||
| MannKind Corp. (MNKD) | Pfizer Inc. | Companies did not complete the deal for MannKind to purchase Pfizer's German insulin manufacturing plant because Sanofi-Aventis Group exercised its right of first refusal and bought the facility | MannKind still paid $3M in cash to acquire bulk insulin and a related manufacturing license (6/22) |
| MAP Pharmaceuticals Inc. (MAPP) | AstraZeneca plc (UK) | Terminated deal on MAP's unit dose budesonide product | MAP regains all rights to the product, but said it plans to suspend further development of UDB, which failed to improve asthma symptoms over placebo in a pediatric Phase III trial (7/9) |
| Neuromed Pharmaceuticals Inc.* | Merck & Co. Inc. | Ended an agreement focused on pain therapeutics, or N-type calcium channel blockers | Merck said none of the compounds generated met the profile necessary to advance them; the deal, started in 2006, was valued at up to $475M (6/11) |
| NexMed Inc. (NEXM) | Novartis AG (Switzerland) | Terminated a licensing agreement for NM100060, a topically applied treatment for onychomycosis | Novartis opted against filing an NDA last year following a Phase III miss (7/8) |
| Synta Pharmaceuticals Corp. (SNTA) | GlaxoSmithKline plc (UK) | Ended agreement for the development and commercialization of elesclomol, effective no later than Sept. 10 | Worldwide rights to elesclomol will revert to Synta, and the company may pay GSK a low single-digit royalty on any potential future sales (6/15) |
|
Notes: # The information in the chart does not cover agreements between biotech companies or agricultural agreements. * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market.BE = Berlin Stock Exchange; FSE = Frankfurth Stock Exchange. | |||
